82 results
Page 3 of 5
8-K
ozilnjvqtld3
7 Jan 21
Entry into a Material Definitive Agreement
7:08am
8-K
EX-99.1
6vzzmin td
7 Jan 21
Entry into a Material Definitive Agreement
7:08am
8-K
EX-99.1
rsxasmq
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
x327s
7 May 20
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
7:44am
8-K
EX-99.1
mx86pv4vqx1u8 fglevi
7 May 20
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
7:44am
8-K
bsikr2z fkpvr2vr
9 Jan 20
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5:22pm
8-K
EX-99.1
3y7xyta4l1cb0p 50
9 Jan 20
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5:22pm
8-K
abcwdp
7 Jan 20
Results of Operations and Financial Condition
4:21pm
8-K
EX-10.1
8ujm50mxk0qr
7 Oct 19
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
dn4mil3m n9cx5hml
16 Sep 19
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
5:17pm
8-K
930a7 2gus
16 Sep 19
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
5:17pm
8-K
5gx7n4
12 Sep 19
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
8:34am
8-K
EX-99.1
5x7rxkni
12 Sep 19
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
8:34am
8-K
nt3azyylxr
11 Sep 19
Apellis Pharmaceuticals Announces Proposed Private Offering of
5:13pm
8-K
EX-99.1
zm9 35u2zgu9rjz
11 Sep 19
Apellis Pharmaceuticals Announces Proposed Private Offering of
5:13pm